Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eteplirsen in young patients with DMD
NCT03218995Phase 2Completed
- Sponsor
- Sarepta Therapeutics
- Start
- Aug 2017
- Primary completion
- Mar 2021
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 4
01
Overview
A Phase 2 trial of eteplirsen in Duchenne muscular dystrophy (DMD), sponsored by Sarepta Therapeutics. Started Aug 2017; status: completed.
02
Drugs
eteplirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03218995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03218995.